Leerink Partnrs Has Negative Outlook of ACHC FY2024 Earnings

Acadia Healthcare Company, Inc. (NASDAQ:ACHC) – Leerink Partnrs dropped their FY2024 earnings per share estimates for shares of Acadia Healthcare in a research report issued to clients and investors on Friday, November 1st. Leerink Partnrs analyst W. Mayo now forecasts that the company will post earnings of $3.42 per share for the year, down from their prior estimate of $3.50. The consensus estimate for Acadia Healthcare’s current full-year earnings is $3.38 per share. Leerink Partnrs also issued estimates for Acadia Healthcare’s Q4 2024 earnings at $0.73 EPS, Q1 2025 earnings at $0.76 EPS, Q2 2025 earnings at $0.97 EPS and Q3 2025 earnings at $0.95 EPS.

Acadia Healthcare (NASDAQ:ACHC) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.90 by $0.01. The company had revenue of $815.60 million during the quarter, compared to the consensus estimate of $819.42 million. Acadia Healthcare had a net margin of 8.99% and a return on equity of 11.12%. Acadia Healthcare’s revenue was up 8.7% on a year-over-year basis. During the same period in the prior year, the company earned $0.91 EPS.

ACHC has been the topic of several other reports. Royal Bank of Canada reissued an “outperform” rating and set a $94.00 target price on shares of Acadia Healthcare in a research report on Friday, September 20th. Barclays reduced their price objective on Acadia Healthcare from $83.00 to $76.00 and set an “overweight” rating for the company in a research report on Monday, September 30th. Deutsche Bank Aktiengesellschaft increased their price target on shares of Acadia Healthcare from $70.00 to $75.00 and gave the stock a “hold” rating in a research report on Friday, August 2nd. KeyCorp initiated coverage on Acadia Healthcare in a report on Friday, October 11th. They set a “sector weight” rating for the company. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $90.00 target price on shares of Acadia Healthcare in a research note on Tuesday, October 1st. One analyst has rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $86.67.

Acadia Healthcare Price Performance

ACHC opened at $42.02 on Monday. Acadia Healthcare has a 12-month low of $41.75 and a 12-month high of $87.77. The company has a quick ratio of 1.18, a current ratio of 1.07 and a debt-to-equity ratio of 0.60. The firm has a market capitalization of $3.90 billion, a P/E ratio of 13.78, a PEG ratio of 1.28 and a beta of 1.33. The stock has a fifty day moving average of $65.72 and a 200-day moving average of $67.77.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Blue Trust Inc. grew its holdings in shares of Acadia Healthcare by 86.1% in the second quarter. Blue Trust Inc. now owns 536 shares of the company’s stock worth $36,000 after purchasing an additional 248 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of Acadia Healthcare by 57.1% during the third quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock valued at $42,000 after purchasing an additional 241 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Acadia Healthcare in the 2nd quarter worth approximately $59,000. Covestor Ltd raised its stake in Acadia Healthcare by 834.4% during the third quarter. Covestor Ltd now owns 1,140 shares of the company’s stock valued at $72,000 after buying an additional 1,018 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale purchased a new position in Acadia Healthcare in the third quarter worth about $86,000.

Acadia Healthcare Company Profile

Acadia Healthcare Company, Inc provides behavioral healthcare services in the United States and Puerto Rico. The company develops and operates acute inpatient psychiatric facilities, specialty treatment facilities comprising residential recovery facilities and eating disorder facilities, comprehensive treatment centers, and residential treatment centers, as well as facilities offering outpatient behavioral healthcare services for the behavioral healthcare and recovery needs of communities.